Qiong Wang
Qiong Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Friedman
Health & Biosciences, International Flavors & Fragrances, Inc. (IFF), Wilmington, DE 19803, USA
1 shared publication - Arthur C. Ouwehand
IFF Health and Biosciences, 02460 Kantvik, Finland
1 shared publication - Ashley A. Hibberd
International Flavors & Fragrances (United States), New York, United States, USA
1 shared publication - Helene Kane
Health & Biosciences, International Flavors & Fragrances, Inc. (IFF), Wilmington, DE 19803, USA
1 shared publication - Henrik Max Jensen
IFF, Health & Biosciences, Edwin Rahrs Vej 38, 8220 Brabrand, Denmark
1 shared publication - Hye-Sook Kim
Health & Biosciences, International Flavors & Fragrances, Inc. (IFF), Wilmington, DE 19803, USA
1 shared publication
Latest Publications
- Open Access
Protease and Betaine for Canine Oral Health: From Biofilm Disruption to Oral Microbiome Evaluation
Periodontal disease (PD) is highly prevalent in dogs and is associated with oral biofilms that promote chronic inflammation and tissue damage. Disrupting biofilms may therefore support canine oral health. This study evaluated protease (subtilisin) and betaine using complementary in vitro and in vivo approaches. Porphyromonas gingivalis, Porphyromonas gulae, and Streptococcus mutans were used as model oral pathogens in biofilm inhibition, biofilm removal, and planktonic growth assays. An 8-day canine pilot study assessed the tolerability of a dental chew containing protease and betaine and its effects on the oral microbiome. In vitro data were analyzed using standard least-squares models, and microbiome responses using diversity and differential abundance analyses. Protease reduced biofilm formation by P. gingivalis and S. mutans (p < 0.0001) and removed established biofilms (p < 0.05), while showing limited effects on planktonic growth. Betaine responses varied by bacterial strain and assay type and did not significantly interact with protease. The chew showed good physiological tolerability, although not all dogs consumed it completely. Microbiome analysis revealed limited treatment effects, with no differences in alpha diversity between groups. Overall, protease was the main driver of biofilm-related responses, supporting further investigation in canine oral care products; however, clinical periodontal outcomes, inflammatory biomarkers, and direct evidence of betaine-mediated tissue protection were not assessed.
Open AccessProtease and Betaine for Canine Oral Health: From Biofilm Disruption to Oral Microbiome Evaluation
Periodontal disease (PD) is highly prevalent in dogs and is associated with oral biofilms that promote chronic inflammation and tissue damage. Disrupting biofilms may therefore support canine oral health. This study evaluated protease (subtilisin) and betaine using complementary in vitro and in vivo approaches. Porphyromonas gingivalis, Porphyromonas gulae, and Streptococcus mutans were used as model oral pathogens in biofilm inhibition, biofilm removal, and planktonic growth assays. An 8-day canine pilot study assessed the tolerability of a dental chew containing protease and betaine and its effects on the oral microbiome. In vitro data were analyzed using standard least-squares models, and microbiome responses using diversity and differential abundance analyses. Protease reduced biofilm formation by P. gingivalis and S. mutans (p < 0.0001) and removed established biofilms (p < 0.05), while showing limited effects on planktonic growth. Betaine responses varied by bacterial strain and assay type and did not significantly interact with protease. The chew showed good physiological tolerability, although not all dogs consumed it completely. Microbiome analysis revealed limited treatment effects, with no differences in alpha diversity between groups. Overall, protease was the main driver of biofilm-related responses, supporting further investigation in canine oral care products; however, clinical periodontal outcomes, inflammatory biomarkers, and direct evidence of betaine-mediated tissue protection were not assessed.
- Open Access
- 27 November 2024
- Published by Elsevier in Poultry Science
- Vol. 104 (1) , 104550
A cross-study analysis of the effect of a dual-strain probiotic applied via the waterline on the growth performance and gut health of broilers under a mild necrotic enteritis challenge
- 27 November 2024
- Published by Elsevier in Poultry Science
- Vol. 104 (1) , 104550
Open AccessA cross-study analysis of the effect of a dual-strain probiotic applied via the waterline on the growth performance and gut health of broilers under a mild necrotic enteritis challenge
- Top Cited PapersOpen Access
- 11 April 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (4) , e0106323
Updated RDP taxonomy and RDP Classifier for more accurate taxonomic classification
The RDP Classifier is one of the most popular machine learning approaches for taxonomic classification due to its robustness and relatively high accuracy. Both the RDP taxonomy and RDP Classifier have been updated to incorporate newly described taxa and recent changes to prokaryotic nomenclature.
- 11 April 2024
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 13 (4) , e0106323
Top Cited PapersOpen AccessUpdated RDP taxonomy and RDP Classifier for more accurate taxonomic classification
The RDP Classifier is one of the most popular machine learning approaches for taxonomic classification due to its robustness and relatively high accuracy. Both the RDP taxonomy and RDP Classifier have been updated to incorporate newly described taxa and recent changes to prokaryotic nomenclature.
- Open Access
Identification and Characterization of a Novel Species of Genus Akkermansia with Metabolic Health Effects in a Diet-Induced Obesity Mouse Model
Akkermansia muciniphila is a well-known bacterium with the ability to degrade mucin. This metabolic capability is believed to play an important role in the colonization of this bacterium in the gut. In this study, we report the identification and characterization of a novel Akkermansia sp. DSM 33459 isolated from human feces of a healthy donor. Phylogenetic analysis based on the genome-wide average nucleotide identity indicated that the Akkermansia sp. DSM 33459 has only 87.5% similarity with the type strain A. muciniphila ATCC BAA-835. Akkermansia sp. DSM 33459 showed significant differences in its fatty acid profile and carbon utilization as compared to the type strain. The Akkermansia sp. DSM 33459 strain was tested in a preclinical obesity model to determine its effect on metabolic markers. Akkermansia sp. DSM 33459 showed significant improvement in body weight, total fat weight, and resistin and insulin levels. Interestingly, these effects were more pronounced with the live form as compared to a pasteurized form of the strain. The strain showed production of agmatine, suggesting a potential novel mechanism for supporting metabolic and cognitive health. Based on its phenotypic features and phylogenetic position, it is proposed that this isolate represents a novel species in the genus Akkermansia and a promising therapeutic candidate for the management of metabolic diseases.
Open AccessIdentification and Characterization of a Novel Species of Genus Akkermansia with Metabolic Health Effects in a Diet-Induced Obesity Mouse Model
Akkermansia muciniphila is a well-known bacterium with the ability to degrade mucin. This metabolic capability is believed to play an important role in the colonization of this bacterium in the gut. In this study, we report the identification and characterization of a novel Akkermansia sp. DSM 33459 isolated from human feces of a healthy donor. Phylogenetic analysis based on the genome-wide average nucleotide identity indicated that the Akkermansia sp. DSM 33459 has only 87.5% similarity with the type strain A. muciniphila ATCC BAA-835. Akkermansia sp. DSM 33459 showed significant differences in its fatty acid profile and carbon utilization as compared to the type strain. The Akkermansia sp. DSM 33459 strain was tested in a preclinical obesity model to determine its effect on metabolic markers. Akkermansia sp. DSM 33459 showed significant improvement in body weight, total fat weight, and resistin and insulin levels. Interestingly, these effects were more pronounced with the live form as compared to a pasteurized form of the strain. The strain showed production of agmatine, suggesting a potential novel mechanism for supporting metabolic and cognitive health. Based on its phenotypic features and phylogenetic position, it is proposed that this isolate represents a novel species in the genus Akkermansia and a promising therapeutic candidate for the management of metabolic diseases.